A PHASE II OPEN-LABEL MULTICOHORT MULTICENTER STUDY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND CHILD-PUGH B CIRRHOSIS

Brief description of study

This is study is for patients with liver cancer (specifically unresectable hepatocellular carcinoma with child-pugh B7 and B8 cirrhosis) that can't be removed with surgery. The study team is testing two different treatments: one with atezolizumab and bevacizumab, and another with just atezolizumab. The study wants to see how few side effects there are and how helpful these treatments are for patients with liver cirrhosis who haven't had any other systemic therapy before. The study will check for side effects and monitor lab results. Patients will keep getting their treatment until their health gets worse or they don't benefit from treatment anymore. In cases where the scan may show the cancer growing but it is not getting worse, and patients still seem to be benefiting from treatment and their overall health is okay, they can continue with treatment. The study will check the tumors at certain times, and the study team will analyze the results around 3 months after the last person starts treatment or until the last patient leaves the study, whichever happens first.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.